IVERIC bio (NASDAQ:ISEE) Issues Earnings Results

IVERIC bio (NASDAQ:ISEE) issued its quarterly earnings data on Thursday. The company reported ($0.35) earnings per share (EPS) for the quarter, Morningstar.com reports.

NASDAQ ISEE traded down $0.01 during trading hours on Friday, reaching $1.16. The company’s stock had a trading volume of 221,062 shares, compared to its average volume of 78,342. The company’s fifty day simple moving average is $1.25. The firm has a market capitalization of $49.36 million, a PE ratio of -0.69 and a beta of 1.17. IVERIC bio has a 52 week low of $1.02 and a 52 week high of $2.60.

ISEE has been the subject of a number of research reports. Zacks Investment Research lowered shares of IVERIC bio from a “hold” rating to a “sell” rating in a report on Tuesday, June 4th. ValuEngine upgraded shares of IVERIC bio from a “hold” rating to a “buy” rating in a report on Thursday.

In other IVERIC bio news, insider Glenn Sblendorio acquired 25,000 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The stock was acquired at an average price of $1.48 per share, for a total transaction of $37,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.30% of the stock is owned by company insiders.

An institutional investor recently bought a new position in IVERIC bio stock. Gabelli Funds LLC bought a new position in IVERIC bio Inc (NASDAQ:ISEE) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 20,000 shares of the company’s stock, valued at approximately $26,000. 40.57% of the stock is currently owned by institutional investors and hedge funds.

IVERIC bio Company Profile

IVERIC bio, Inc, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD).

See Also: How to trade on quiet period expirations

Earnings History for IVERIC bio (NASDAQ:ISEE)

Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.